SRC and pulmonary hypertension: Nonclinical evidence has pointed to the inhibition of src kinases as a possible method of therapy for the pulmonary vascular remodeling and right ventricular hypertrophy in pulmonary hypertension [4], although several reports indicate that dual Abl/src inhibitor dasatinib may actually induce pulmonary hypertension [5,6,7]; it was more recently suggested that this dasatinib effect may in fact be independent of the src inhibition [7].